nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP3A4—Thiotepa—urinary bladder cancer	0.0549	0.402	CbGbCtD
Sitaxentan—CYP2C9—Fluorouracil—urinary bladder cancer	0.0307	0.224	CbGbCtD
Sitaxentan—CYP2C9—Cisplatin—urinary bladder cancer	0.0261	0.191	CbGbCtD
Sitaxentan—EDNRB—prostate gland—urinary bladder cancer	0.0167	0.123	CbGeAlD
Sitaxentan—CYP2C19—urine—urinary bladder cancer	0.0164	0.121	CbGeAlD
Sitaxentan—CYP3A4—Etoposide—urinary bladder cancer	0.0149	0.109	CbGbCtD
Sitaxentan—EDNRA—prostate gland—urinary bladder cancer	0.0138	0.102	CbGeAlD
Sitaxentan—CYP2C9—urine—urinary bladder cancer	0.0127	0.0936	CbGeAlD
Sitaxentan—EDNRA—seminal vesicle—urinary bladder cancer	0.0116	0.0859	CbGeAlD
Sitaxentan—EDNRB—urethra—urinary bladder cancer	0.0112	0.0823	CbGeAlD
Sitaxentan—CYP3A4—Doxorubicin—urinary bladder cancer	0.0102	0.0743	CbGbCtD
Sitaxentan—CYP3A4—urine—urinary bladder cancer	0.00968	0.0714	CbGeAlD
Sitaxentan—EDNRA—urethra—urinary bladder cancer	0.00922	0.068	CbGeAlD
Sitaxentan—EDNRB—vagina—urinary bladder cancer	0.00822	0.0607	CbGeAlD
Sitaxentan—EDNRA—vagina—urinary bladder cancer	0.0068	0.0501	CbGeAlD
Sitaxentan—EDNRB—lymph node—urinary bladder cancer	0.00532	0.0392	CbGeAlD
Sitaxentan—EDNRA—lymph node—urinary bladder cancer	0.0044	0.0324	CbGeAlD
Sitaxentan—CYP2C19—vagina—urinary bladder cancer	0.0029	0.0214	CbGeAlD
Sitaxentan—CYP2C9—female reproductive system—urinary bladder cancer	0.00249	0.0183	CbGeAlD
Sitaxentan—CYP3A4—renal system—urinary bladder cancer	0.00237	0.0175	CbGeAlD
Sitaxentan—CYP3A4—female reproductive system—urinary bladder cancer	0.0019	0.014	CbGeAlD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000648	0.00949	CbGpPWpGaD
Sitaxentan—CYP2C9—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000645	0.00945	CbGpPWpGaD
Sitaxentan—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000592	0.00867	CbGpPWpGaD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000539	0.0079	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelins—SRC—urinary bladder cancer	0.000535	0.00784	CbGpPWpGaD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000527	0.00772	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelins—HRAS—urinary bladder cancer	0.000526	0.00771	CbGpPWpGaD
Sitaxentan—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00052	0.00762	CbGpPWpGaD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000492	0.00721	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—GSTZ1—urinary bladder cancer	0.000483	0.00708	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000477	0.00699	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—GSTO2—urinary bladder cancer	0.000458	0.00671	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—NAT1—urinary bladder cancer	0.000458	0.00671	CbGpPWpGaD
Sitaxentan—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000454	0.00665	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000452	0.00662	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	0.000441	0.00646	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000435	0.00637	CbGpPWpGaD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000427	0.00626	CbGpPWpGaD
Sitaxentan—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000425	0.00624	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—UGT2B7—urinary bladder cancer	0.000419	0.00614	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.000418	0.00612	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.000418	0.00612	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000413	0.00606	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000412	0.00604	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.000382	0.0056	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—CYP4B1—urinary bladder cancer	0.000377	0.00553	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000377	0.00552	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelins—HRAS—urinary bladder cancer	0.000377	0.00552	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000372	0.00545	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	0.000371	0.00543	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000344	0.00504	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000339	0.00497	CbGpPWpGaD
Sitaxentan—Haematuria—Methotrexate—urinary bladder cancer	0.000327	0.000496	CcSEcCtD
Sitaxentan—Weight decreased—Epirubicin—urinary bladder cancer	0.000326	0.000494	CcSEcCtD
Sitaxentan—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000325	0.000492	CcSEcCtD
Sitaxentan—Somnolence—Etoposide—urinary bladder cancer	0.000325	0.000492	CcSEcCtD
Sitaxentan—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000324	0.000492	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000324	0.000492	CcSEcCtD
Sitaxentan—Epistaxis—Methotrexate—urinary bladder cancer	0.000323	0.00049	CcSEcCtD
Sitaxentan—Vomiting—Thiotepa—urinary bladder cancer	0.000323	0.00049	CcSEcCtD
Sitaxentan—Infestation NOS—Epirubicin—urinary bladder cancer	0.000321	0.000487	CcSEcCtD
Sitaxentan—Infestation—Epirubicin—urinary bladder cancer	0.000321	0.000487	CcSEcCtD
Sitaxentan—Rash—Thiotepa—urinary bladder cancer	0.000321	0.000486	CcSEcCtD
Sitaxentan—Bronchitis—Doxorubicin—urinary bladder cancer	0.00032	0.000486	CcSEcCtD
Sitaxentan—Dermatitis—Thiotepa—urinary bladder cancer	0.00032	0.000486	CcSEcCtD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000319	0.00468	CbGpPWpGaD
Sitaxentan—Headache—Thiotepa—urinary bladder cancer	0.000318	0.000483	CcSEcCtD
Sitaxentan—Decreased appetite—Etoposide—urinary bladder cancer	0.000317	0.000481	CcSEcCtD
Sitaxentan—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000316	0.00048	CcSEcCtD
Sitaxentan—Renal failure—Epirubicin—urinary bladder cancer	0.000315	0.000478	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000315	0.000478	CcSEcCtD
Sitaxentan—Body temperature increased—Cisplatin—urinary bladder cancer	0.000315	0.000478	CcSEcCtD
Sitaxentan—Fatigue—Etoposide—urinary bladder cancer	0.000315	0.000477	CcSEcCtD
Sitaxentan—Jaundice—Epirubicin—urinary bladder cancer	0.000313	0.000474	CcSEcCtD
Sitaxentan—Stomatitis—Epirubicin—urinary bladder cancer	0.000313	0.000474	CcSEcCtD
Sitaxentan—Constipation—Etoposide—urinary bladder cancer	0.000312	0.000473	CcSEcCtD
Sitaxentan—Pain—Etoposide—urinary bladder cancer	0.000312	0.000473	CcSEcCtD
Sitaxentan—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000312	0.000473	CcSEcCtD
Sitaxentan—Dysuria—Doxorubicin—urinary bladder cancer	0.000311	0.000472	CcSEcCtD
Sitaxentan—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00031	0.00047	CcSEcCtD
Sitaxentan—Haemoglobin—Methotrexate—urinary bladder cancer	0.000309	0.000469	CcSEcCtD
Sitaxentan—Haemorrhage—Methotrexate—urinary bladder cancer	0.000308	0.000467	CcSEcCtD
Sitaxentan—Hepatitis—Methotrexate—urinary bladder cancer	0.000308	0.000467	CcSEcCtD
Sitaxentan—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000308	0.000467	CcSEcCtD
Sitaxentan—Asthenia—Gemcitabine—urinary bladder cancer	0.000307	0.000465	CcSEcCtD
Sitaxentan—Haematuria—Epirubicin—urinary bladder cancer	0.000306	0.000464	CcSEcCtD
Sitaxentan—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000304	0.000461	CcSEcCtD
Sitaxentan—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000304	0.000461	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000304	0.00046	CcSEcCtD
Sitaxentan—Epistaxis—Epirubicin—urinary bladder cancer	0.000303	0.000459	CcSEcCtD
Sitaxentan—Nausea—Thiotepa—urinary bladder cancer	0.000302	0.000458	CcSEcCtD
Sitaxentan—Urethral disorder—Methotrexate—urinary bladder cancer	0.000302	0.000458	CcSEcCtD
Sitaxentan—Weight decreased—Doxorubicin—urinary bladder cancer	0.000301	0.000457	CcSEcCtD
Sitaxentan—Sinusitis—Epirubicin—urinary bladder cancer	0.000301	0.000457	CcSEcCtD
Sitaxentan—Feeling abnormal—Etoposide—urinary bladder cancer	0.000301	0.000456	CcSEcCtD
Sitaxentan—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.0003	0.000456	CcSEcCtD
Sitaxentan—Infestation—Doxorubicin—urinary bladder cancer	0.000297	0.00045	CcSEcCtD
Sitaxentan—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000297	0.00045	CcSEcCtD
Sitaxentan—Visual impairment—Methotrexate—urinary bladder cancer	0.000297	0.00045	CcSEcCtD
Sitaxentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000296	0.00434	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000294	0.000445	CcSEcCtD
Sitaxentan—Bradycardia—Epirubicin—urinary bladder cancer	0.000293	0.000445	CcSEcCtD
Sitaxentan—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000293	0.000444	CcSEcCtD
Sitaxentan—Renal failure—Doxorubicin—urinary bladder cancer	0.000292	0.000443	CcSEcCtD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000291	0.00426	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000291	0.00426	CbGpPWpGaD
Sitaxentan—Urticaria—Etoposide—urinary bladder cancer	0.00029	0.00044	CcSEcCtD
Sitaxentan—Haemoglobin—Epirubicin—urinary bladder cancer	0.00029	0.000439	CcSEcCtD
Sitaxentan—Jaundice—Doxorubicin—urinary bladder cancer	0.000289	0.000439	CcSEcCtD
Sitaxentan—Stomatitis—Doxorubicin—urinary bladder cancer	0.000289	0.000439	CcSEcCtD
Sitaxentan—Rhinitis—Epirubicin—urinary bladder cancer	0.000289	0.000438	CcSEcCtD
Sitaxentan—Body temperature increased—Etoposide—urinary bladder cancer	0.000289	0.000438	CcSEcCtD
Sitaxentan—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000289	0.000438	CcSEcCtD
Sitaxentan—Hepatitis—Epirubicin—urinary bladder cancer	0.000288	0.000437	CcSEcCtD
Sitaxentan—Haemorrhage—Epirubicin—urinary bladder cancer	0.000288	0.000437	CcSEcCtD
Sitaxentan—Eye disorder—Methotrexate—urinary bladder cancer	0.000288	0.000436	CcSEcCtD
Sitaxentan—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000288	0.000436	CcSEcCtD
Sitaxentan—Tinnitus—Methotrexate—urinary bladder cancer	0.000287	0.000435	CcSEcCtD
Sitaxentan—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000287	0.0042	CbGpPWpGaD
Sitaxentan—Asthenia—Cisplatin—urinary bladder cancer	0.000286	0.000434	CcSEcCtD
Sitaxentan—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000286	0.000433	CcSEcCtD
Sitaxentan—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000285	0.000431	CcSEcCtD
Sitaxentan—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000284	0.00043	CcSEcCtD
Sitaxentan—Haematuria—Doxorubicin—urinary bladder cancer	0.000283	0.000429	CcSEcCtD
Sitaxentan—Urethral disorder—Epirubicin—urinary bladder cancer	0.000282	0.000428	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000281	0.000426	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—HDAC4—urinary bladder cancer	0.000281	0.00411	CbGpPWpGaD
Sitaxentan—Epistaxis—Doxorubicin—urinary bladder cancer	0.00028	0.000425	CcSEcCtD
Sitaxentan—Angiopathy—Methotrexate—urinary bladder cancer	0.000279	0.000424	CcSEcCtD
Sitaxentan—Sinusitis—Doxorubicin—urinary bladder cancer	0.000279	0.000422	CcSEcCtD
Sitaxentan—Immune system disorder—Methotrexate—urinary bladder cancer	0.000278	0.000422	CcSEcCtD
Sitaxentan—Dizziness—Fluorouracil—urinary bladder cancer	0.000278	0.000422	CcSEcCtD
Sitaxentan—Visual impairment—Epirubicin—urinary bladder cancer	0.000278	0.000421	CcSEcCtD
Sitaxentan—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000277	0.000421	CcSEcCtD
Sitaxentan—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000276	0.00404	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000276	0.00404	CbGpPWpGaD
Sitaxentan—Diarrhoea—Cisplatin—urinary bladder cancer	0.000273	0.000414	CcSEcCtD
Sitaxentan—Alopecia—Methotrexate—urinary bladder cancer	0.000272	0.000413	CcSEcCtD
Sitaxentan—Vomiting—Gemcitabine—urinary bladder cancer	0.000272	0.000412	CcSEcCtD
Sitaxentan—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000272	0.00398	CbGpPWpGaD
Sitaxentan—Bradycardia—Doxorubicin—urinary bladder cancer	0.000271	0.000412	CcSEcCtD
Sitaxentan—Mental disorder—Methotrexate—urinary bladder cancer	0.00027	0.000409	CcSEcCtD
Sitaxentan—Rash—Gemcitabine—urinary bladder cancer	0.00027	0.000409	CcSEcCtD
Sitaxentan—Dermatitis—Gemcitabine—urinary bladder cancer	0.000269	0.000408	CcSEcCtD
Sitaxentan—Eye disorder—Epirubicin—urinary bladder cancer	0.000269	0.000408	CcSEcCtD
Sitaxentan—Hypersensitivity—Etoposide—urinary bladder cancer	0.000269	0.000408	CcSEcCtD
Sitaxentan—Tinnitus—Epirubicin—urinary bladder cancer	0.000269	0.000407	CcSEcCtD
Sitaxentan—Malnutrition—Methotrexate—urinary bladder cancer	0.000268	0.000406	CcSEcCtD
Sitaxentan—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000268	0.000406	CcSEcCtD
Sitaxentan—Headache—Gemcitabine—urinary bladder cancer	0.000268	0.000406	CcSEcCtD
Sitaxentan—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000267	0.000405	CcSEcCtD
Sitaxentan—Flushing—Epirubicin—urinary bladder cancer	0.000267	0.000405	CcSEcCtD
Sitaxentan—Vomiting—Fluorouracil—urinary bladder cancer	0.000267	0.000405	CcSEcCtD
Sitaxentan—Rhinitis—Doxorubicin—urinary bladder cancer	0.000267	0.000405	CcSEcCtD
Sitaxentan—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000267	0.000404	CcSEcCtD
Sitaxentan—Hepatitis—Doxorubicin—urinary bladder cancer	0.000267	0.000404	CcSEcCtD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	0.000265	0.00389	CbGpPWpGaD
Sitaxentan—Rash—Fluorouracil—urinary bladder cancer	0.000265	0.000402	CcSEcCtD
Sitaxentan—Dermatitis—Fluorouracil—urinary bladder cancer	0.000265	0.000402	CcSEcCtD
Sitaxentan—Headache—Fluorouracil—urinary bladder cancer	0.000263	0.000399	CcSEcCtD
Sitaxentan—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000263	0.000399	CcSEcCtD
Sitaxentan—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000263	0.000398	CcSEcCtD
Sitaxentan—Asthenia—Etoposide—urinary bladder cancer	0.000262	0.000397	CcSEcCtD
Sitaxentan—Angiopathy—Epirubicin—urinary bladder cancer	0.000261	0.000396	CcSEcCtD
Sitaxentan—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000261	0.000396	CcSEcCtD
Sitaxentan—Immune system disorder—Epirubicin—urinary bladder cancer	0.00026	0.000395	CcSEcCtD
Sitaxentan—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.00026	0.000394	CcSEcCtD
Sitaxentan—Visual impairment—Doxorubicin—urinary bladder cancer	0.000257	0.00039	CcSEcCtD
Sitaxentan—Alopecia—Epirubicin—urinary bladder cancer	0.000255	0.000386	CcSEcCtD
Sitaxentan—Nausea—Gemcitabine—urinary bladder cancer	0.000254	0.000385	CcSEcCtD
Sitaxentan—Vomiting—Cisplatin—urinary bladder cancer	0.000253	0.000384	CcSEcCtD
Sitaxentan—Mental disorder—Epirubicin—urinary bladder cancer	0.000252	0.000383	CcSEcCtD
Sitaxentan—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000252	0.00369	CbGpPWpGaD
Sitaxentan—Rash—Cisplatin—urinary bladder cancer	0.000251	0.000381	CcSEcCtD
Sitaxentan—Dermatitis—Cisplatin—urinary bladder cancer	0.000251	0.000381	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—NAT2—urinary bladder cancer	0.000251	0.00368	CbGpPWpGaD
Sitaxentan—Malnutrition—Epirubicin—urinary bladder cancer	0.000251	0.00038	CcSEcCtD
Sitaxentan—Diarrhoea—Etoposide—urinary bladder cancer	0.00025	0.000379	CcSEcCtD
Sitaxentan—Nausea—Fluorouracil—urinary bladder cancer	0.00025	0.000379	CcSEcCtD
Sitaxentan—Eye disorder—Doxorubicin—urinary bladder cancer	0.000249	0.000378	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000249	0.00364	CbGpPWpGaD
Sitaxentan—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000249	0.000377	CcSEcCtD
Sitaxentan—Tinnitus—Doxorubicin—urinary bladder cancer	0.000249	0.000377	CcSEcCtD
Sitaxentan—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000249	0.00364	CbGpPWpGaD
Sitaxentan—Anaemia—Methotrexate—urinary bladder cancer	0.000248	0.000376	CcSEcCtD
Sitaxentan—CYP2C19—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000248	0.00363	CbGpPWpGaD
Sitaxentan—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000247	0.000375	CcSEcCtD
Sitaxentan—Flushing—Doxorubicin—urinary bladder cancer	0.000247	0.000375	CcSEcCtD
Sitaxentan—Tension—Epirubicin—urinary bladder cancer	0.000246	0.000373	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	0.000245	0.0036	CbGpPWpGaD
Sitaxentan—Nervousness—Epirubicin—urinary bladder cancer	0.000244	0.000369	CcSEcCtD
Sitaxentan—Angiopathy—Doxorubicin—urinary bladder cancer	0.000242	0.000367	CcSEcCtD
Sitaxentan—Malaise—Methotrexate—urinary bladder cancer	0.000242	0.000366	CcSEcCtD
Sitaxentan—Dizziness—Etoposide—urinary bladder cancer	0.000241	0.000366	CcSEcCtD
Sitaxentan—Muscle spasms—Epirubicin—urinary bladder cancer	0.000241	0.000366	CcSEcCtD
Sitaxentan—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000241	0.000365	CcSEcCtD
Sitaxentan—Vertigo—Methotrexate—urinary bladder cancer	0.000241	0.000365	CcSEcCtD
Sitaxentan—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.00024	0.000364	CcSEcCtD
Sitaxentan—Leukopenia—Methotrexate—urinary bladder cancer	0.00024	0.000364	CcSEcCtD
Sitaxentan—Nausea—Cisplatin—urinary bladder cancer	0.000237	0.000359	CcSEcCtD
Sitaxentan—Alopecia—Doxorubicin—urinary bladder cancer	0.000236	0.000357	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—GLI1—urinary bladder cancer	0.000235	0.00344	CbGpPWpGaD
Sitaxentan—Mental disorder—Doxorubicin—urinary bladder cancer	0.000234	0.000354	CcSEcCtD
Sitaxentan—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000233	0.000353	CcSEcCtD
Sitaxentan—Vomiting—Etoposide—urinary bladder cancer	0.000232	0.000352	CcSEcCtD
Sitaxentan—Malnutrition—Doxorubicin—urinary bladder cancer	0.000232	0.000352	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	0.000232	0.0034	CbGpPWpGaD
Sitaxentan—Anaemia—Epirubicin—urinary bladder cancer	0.000232	0.000351	CcSEcCtD
Sitaxentan—Agitation—Epirubicin—urinary bladder cancer	0.00023	0.000349	CcSEcCtD
Sitaxentan—Rash—Etoposide—urinary bladder cancer	0.00023	0.000349	CcSEcCtD
Sitaxentan—Dermatitis—Etoposide—urinary bladder cancer	0.00023	0.000349	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000229	0.00335	CbGpPWpGaD
Sitaxentan—Headache—Etoposide—urinary bladder cancer	0.000229	0.000347	CcSEcCtD
Sitaxentan—Chest pain—Methotrexate—urinary bladder cancer	0.000228	0.000346	CcSEcCtD
Sitaxentan—Tension—Doxorubicin—urinary bladder cancer	0.000228	0.000345	CcSEcCtD
Sitaxentan—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000227	0.00333	CbGpPWpGaD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000227	0.000344	CcSEcCtD
Sitaxentan—Malaise—Epirubicin—urinary bladder cancer	0.000226	0.000343	CcSEcCtD
Sitaxentan—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000226	0.00331	CbGpPWpGaD
Sitaxentan—Discomfort—Methotrexate—urinary bladder cancer	0.000225	0.000342	CcSEcCtD
Sitaxentan—Nervousness—Doxorubicin—urinary bladder cancer	0.000225	0.000342	CcSEcCtD
Sitaxentan—Vertigo—Epirubicin—urinary bladder cancer	0.000225	0.000342	CcSEcCtD
Sitaxentan—Leukopenia—Epirubicin—urinary bladder cancer	0.000224	0.00034	CcSEcCtD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000224	0.00328	CbGpPWpGaD
Sitaxentan—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000223	0.000338	CcSEcCtD
Sitaxentan—Confusional state—Methotrexate—urinary bladder cancer	0.000221	0.000334	CcSEcCtD
Sitaxentan—Infection—Methotrexate—urinary bladder cancer	0.000217	0.000329	CcSEcCtD
Sitaxentan—Nausea—Etoposide—urinary bladder cancer	0.000217	0.000329	CcSEcCtD
Sitaxentan—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000215	0.000326	CcSEcCtD
Sitaxentan—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000214	0.000325	CcSEcCtD
Sitaxentan—Anaemia—Doxorubicin—urinary bladder cancer	0.000214	0.000325	CcSEcCtD
Sitaxentan—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000214	0.000325	CcSEcCtD
Sitaxentan—Chest pain—Epirubicin—urinary bladder cancer	0.000214	0.000324	CcSEcCtD
Sitaxentan—Agitation—Doxorubicin—urinary bladder cancer	0.000213	0.000323	CcSEcCtD
Sitaxentan—Skin disorder—Methotrexate—urinary bladder cancer	0.000212	0.000322	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000212	0.000322	CcSEcCtD
Sitaxentan—Discomfort—Epirubicin—urinary bladder cancer	0.000211	0.00032	CcSEcCtD
Sitaxentan—Malaise—Doxorubicin—urinary bladder cancer	0.000209	0.000317	CcSEcCtD
Sitaxentan—Dry mouth—Epirubicin—urinary bladder cancer	0.000209	0.000317	CcSEcCtD
Sitaxentan—Vertigo—Doxorubicin—urinary bladder cancer	0.000208	0.000316	CcSEcCtD
Sitaxentan—Anorexia—Methotrexate—urinary bladder cancer	0.000208	0.000316	CcSEcCtD
Sitaxentan—Leukopenia—Doxorubicin—urinary bladder cancer	0.000208	0.000315	CcSEcCtD
Sitaxentan—Confusional state—Epirubicin—urinary bladder cancer	0.000206	0.000313	CcSEcCtD
Sitaxentan—Oedema—Epirubicin—urinary bladder cancer	0.000205	0.00031	CcSEcCtD
Sitaxentan—Hypotension—Methotrexate—urinary bladder cancer	0.000204	0.00031	CcSEcCtD
Sitaxentan—Infection—Epirubicin—urinary bladder cancer	0.000203	0.000308	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—HDAC4—urinary bladder cancer	0.000201	0.00294	CbGpPWpGaD
Sitaxentan—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000201	0.000304	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—HPGDS—urinary bladder cancer	0.000201	0.00294	CbGpPWpGaD
Sitaxentan—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.0002	0.000304	CcSEcCtD
Sitaxentan—Tachycardia—Epirubicin—urinary bladder cancer	0.0002	0.000303	CcSEcCtD
Sitaxentan—Skin disorder—Epirubicin—urinary bladder cancer	0.000199	0.000301	CcSEcCtD
Sitaxentan—Insomnia—Methotrexate—urinary bladder cancer	0.000198	0.0003	CcSEcCtD
Sitaxentan—Chest pain—Doxorubicin—urinary bladder cancer	0.000198	0.0003	CcSEcCtD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	0.000197	0.00289	CbGpPWpGaD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000196	0.000298	CcSEcCtD
Sitaxentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000195	0.00286	CbGpPWpGaD
Sitaxentan—Discomfort—Doxorubicin—urinary bladder cancer	0.000195	0.000296	CcSEcCtD
Sitaxentan—Anorexia—Epirubicin—urinary bladder cancer	0.000195	0.000296	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—GSTT1—urinary bladder cancer	0.000195	0.00285	CbGpPWpGaD
Sitaxentan—Somnolence—Methotrexate—urinary bladder cancer	0.000194	0.000295	CcSEcCtD
Sitaxentan—Dry mouth—Doxorubicin—urinary bladder cancer	0.000193	0.000293	CcSEcCtD
Sitaxentan—Dyspepsia—Methotrexate—urinary bladder cancer	0.000193	0.000292	CcSEcCtD
Sitaxentan—Hypotension—Epirubicin—urinary bladder cancer	0.000191	0.00029	CcSEcCtD
Sitaxentan—Confusional state—Doxorubicin—urinary bladder cancer	0.000191	0.00029	CcSEcCtD
Sitaxentan—Decreased appetite—Methotrexate—urinary bladder cancer	0.00019	0.000288	CcSEcCtD
Sitaxentan—Oedema—Doxorubicin—urinary bladder cancer	0.000189	0.000287	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000189	0.00278	CbGpPWpGaD
Sitaxentan—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000189	0.000286	CcSEcCtD
Sitaxentan—Fatigue—Methotrexate—urinary bladder cancer	0.000189	0.000286	CcSEcCtD
Sitaxentan—Infection—Doxorubicin—urinary bladder cancer	0.000188	0.000285	CcSEcCtD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000188	0.00275	CbGpPWpGaD
Sitaxentan—Pain—Methotrexate—urinary bladder cancer	0.000187	0.000284	CcSEcCtD
Sitaxentan—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000186	0.000282	CcSEcCtD
Sitaxentan—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000185	0.000281	CcSEcCtD
Sitaxentan—Insomnia—Epirubicin—urinary bladder cancer	0.000185	0.000281	CcSEcCtD
Sitaxentan—Tachycardia—Doxorubicin—urinary bladder cancer	0.000185	0.00028	CcSEcCtD
Sitaxentan—Skin disorder—Doxorubicin—urinary bladder cancer	0.000184	0.000279	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000183	0.00268	CbGpPWpGaD
Sitaxentan—Somnolence—Epirubicin—urinary bladder cancer	0.000182	0.000276	CcSEcCtD
Sitaxentan—Anorexia—Doxorubicin—urinary bladder cancer	0.000181	0.000274	CcSEcCtD
Sitaxentan—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00018	0.000273	CcSEcCtD
Sitaxentan—Dyspepsia—Epirubicin—urinary bladder cancer	0.00018	0.000273	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000178	0.00261	CbGpPWpGaD
Sitaxentan—Decreased appetite—Epirubicin—urinary bladder cancer	0.000178	0.00027	CcSEcCtD
Sitaxentan—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000177	0.0026	CbGpPWpGaD
Sitaxentan—Hypotension—Doxorubicin—urinary bladder cancer	0.000177	0.000268	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000177	0.000268	CcSEcCtD
Sitaxentan—Fatigue—Epirubicin—urinary bladder cancer	0.000176	0.000268	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	0.000176	0.00257	CbGpPWpGaD
Sitaxentan—Pain—Epirubicin—urinary bladder cancer	0.000175	0.000265	CcSEcCtD
Sitaxentan—Constipation—Epirubicin—urinary bladder cancer	0.000175	0.000265	CcSEcCtD
Sitaxentan—Urticaria—Methotrexate—urinary bladder cancer	0.000174	0.000263	CcSEcCtD
Sitaxentan—Body temperature increased—Methotrexate—urinary bladder cancer	0.000173	0.000262	CcSEcCtD
Sitaxentan—Insomnia—Doxorubicin—urinary bladder cancer	0.000171	0.00026	CcSEcCtD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000171	0.00251	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000169	0.000256	CcSEcCtD
Sitaxentan—Somnolence—Doxorubicin—urinary bladder cancer	0.000168	0.000255	CcSEcCtD
Sitaxentan—EDNRA—Signaling Pathways—GLI1—urinary bladder cancer	0.000168	0.00247	CbGpPWpGaD
Sitaxentan—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000167	0.000253	CcSEcCtD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	0.000166	0.00243	CbGpPWpGaD
Sitaxentan—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000165	0.00025	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000164	0.000248	CcSEcCtD
Sitaxentan—Fatigue—Doxorubicin—urinary bladder cancer	0.000163	0.000248	CcSEcCtD
Sitaxentan—Urticaria—Epirubicin—urinary bladder cancer	0.000163	0.000247	CcSEcCtD
Sitaxentan—Constipation—Doxorubicin—urinary bladder cancer	0.000162	0.000246	CcSEcCtD
Sitaxentan—Pain—Doxorubicin—urinary bladder cancer	0.000162	0.000246	CcSEcCtD
Sitaxentan—Body temperature increased—Epirubicin—urinary bladder cancer	0.000162	0.000245	CcSEcCtD
Sitaxentan—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000161	0.000244	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—RBX1—urinary bladder cancer	0.000161	0.00236	CbGpPWpGaD
Sitaxentan—Asthenia—Methotrexate—urinary bladder cancer	0.000157	0.000238	CcSEcCtD
Sitaxentan—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000156	0.000237	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—TSC1—urinary bladder cancer	0.000151	0.00222	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000151	0.00221	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000151	0.000229	CcSEcCtD
Sitaxentan—Urticaria—Doxorubicin—urinary bladder cancer	0.00015	0.000228	CcSEcCtD
Sitaxentan—Body temperature increased—Doxorubicin—urinary bladder cancer	0.00015	0.000227	CcSEcCtD
Sitaxentan—Diarrhoea—Methotrexate—urinary bladder cancer	0.00015	0.000227	CcSEcCtD
Sitaxentan—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000149	0.00218	CbGpPWpGaD
Sitaxentan—Asthenia—Epirubicin—urinary bladder cancer	0.000147	0.000223	CcSEcCtD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000145	0.00212	CbGpPWpGaD
Sitaxentan—Dizziness—Methotrexate—urinary bladder cancer	0.000145	0.000219	CcSEcCtD
Sitaxentan—EDNRB—Signaling Pathways—JAG1—urinary bladder cancer	0.000144	0.00211	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	0.000141	0.00207	CbGpPWpGaD
Sitaxentan—Diarrhoea—Epirubicin—urinary bladder cancer	0.00014	0.000212	CcSEcCtD
Sitaxentan—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00014	0.000212	CcSEcCtD
Sitaxentan—Vomiting—Methotrexate—urinary bladder cancer	0.000139	0.000211	CcSEcCtD
Sitaxentan—Rash—Methotrexate—urinary bladder cancer	0.000138	0.000209	CcSEcCtD
Sitaxentan—Dermatitis—Methotrexate—urinary bladder cancer	0.000138	0.000209	CcSEcCtD
Sitaxentan—Headache—Methotrexate—urinary bladder cancer	0.000137	0.000208	CcSEcCtD
Sitaxentan—Asthenia—Doxorubicin—urinary bladder cancer	0.000136	0.000206	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000136	0.00199	CbGpPWpGaD
Sitaxentan—Dizziness—Epirubicin—urinary bladder cancer	0.000135	0.000205	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	0.000135	0.00198	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000133	0.00195	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000132	0.00194	CbGpPWpGaD
Sitaxentan—Vomiting—Epirubicin—urinary bladder cancer	0.00013	0.000197	CcSEcCtD
Sitaxentan—Nausea—Methotrexate—urinary bladder cancer	0.00013	0.000197	CcSEcCtD
Sitaxentan—Diarrhoea—Doxorubicin—urinary bladder cancer	0.00013	0.000196	CcSEcCtD
Sitaxentan—Rash—Epirubicin—urinary bladder cancer	0.000129	0.000196	CcSEcCtD
Sitaxentan—Dermatitis—Epirubicin—urinary bladder cancer	0.000129	0.000196	CcSEcCtD
Sitaxentan—Headache—Epirubicin—urinary bladder cancer	0.000128	0.000194	CcSEcCtD
Sitaxentan—Dizziness—Doxorubicin—urinary bladder cancer	0.000125	0.00019	CcSEcCtD
Sitaxentan—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	0.000124	0.00182	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000123	0.0018	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000122	0.00179	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000122	0.00179	CbGpPWpGaD
Sitaxentan—Nausea—Epirubicin—urinary bladder cancer	0.000122	0.000184	CcSEcCtD
Sitaxentan—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000121	0.00178	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000121	0.00177	CbGpPWpGaD
Sitaxentan—Vomiting—Doxorubicin—urinary bladder cancer	0.00012	0.000183	CcSEcCtD
Sitaxentan—Rash—Doxorubicin—urinary bladder cancer	0.000119	0.000181	CcSEcCtD
Sitaxentan—Dermatitis—Doxorubicin—urinary bladder cancer	0.000119	0.000181	CcSEcCtD
Sitaxentan—Headache—Doxorubicin—urinary bladder cancer	0.000119	0.00018	CcSEcCtD
Sitaxentan—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000117	0.00172	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—S100B—urinary bladder cancer	0.000117	0.00171	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RBX1—urinary bladder cancer	0.000115	0.00169	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000113	0.00166	CbGpPWpGaD
Sitaxentan—Nausea—Doxorubicin—urinary bladder cancer	0.000112	0.000171	CcSEcCtD
Sitaxentan—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000112	0.00163	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—RHOA—urinary bladder cancer	0.000111	0.00162	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TSC1—urinary bladder cancer	0.000108	0.00159	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000107	0.00157	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—NCOR1—urinary bladder cancer	0.000105	0.00154	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—JAG1—urinary bladder cancer	0.000103	0.00151	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—IL2—urinary bladder cancer	0.000102	0.0015	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CXCL8—urinary bladder cancer	9.72e-05	0.00142	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—IL2—urinary bladder cancer	9.29e-05	0.00136	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TERT—urinary bladder cancer	9.25e-05	0.00136	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—RHOA—urinary bladder cancer	8.72e-05	0.00128	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—FGFR3—urinary bladder cancer	8.49e-05	0.00124	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—S100B—urinary bladder cancer	8.36e-05	0.00122	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	8.27e-05	0.00121	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ESR1—urinary bladder cancer	8.25e-05	0.00121	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	8.11e-05	0.00119	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	8e-05	0.00117	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—RHOA—urinary bladder cancer	7.92e-05	0.00116	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	7.84e-05	0.00115	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NAT1—urinary bladder cancer	7.84e-05	0.00115	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.71e-05	0.00113	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CXCL8—urinary bladder cancer	7.66e-05	0.00112	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	7.54e-05	0.0011	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—NCOR1—urinary bladder cancer	7.51e-05	0.0011	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	7.46e-05	0.00109	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.35e-05	0.00108	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—IL2—urinary bladder cancer	7.32e-05	0.00107	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CREBBP—urinary bladder cancer	7.23e-05	0.00106	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	7.17e-05	0.00105	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NAT1—urinary bladder cancer	7.14e-05	0.00105	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	7.14e-05	0.00105	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IGF1—urinary bladder cancer	7.14e-05	0.00105	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—EGFR—urinary bladder cancer	7.1e-05	0.00104	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.03e-05	0.00103	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CXCL8—urinary bladder cancer	6.96e-05	0.00102	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—KRAS—urinary bladder cancer	6.71e-05	0.000983	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—IL2—urinary bladder cancer	6.65e-05	0.000974	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TERT—urinary bladder cancer	6.62e-05	0.000971	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—RHOA—urinary bladder cancer	6.54e-05	0.000958	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	6.53e-05	0.000958	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	6.45e-05	0.000946	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	6.09e-05	0.000893	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—FGFR3—urinary bladder cancer	6.08e-05	0.000891	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ERBB2—urinary bladder cancer	6.05e-05	0.000887	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	5.94e-05	0.00087	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ESR1—urinary bladder cancer	5.9e-05	0.000865	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	5.88e-05	0.000862	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CXCL8—urinary bladder cancer	5.74e-05	0.000841	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—HRAS—urinary bladder cancer	5.7e-05	0.000836	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	5.56e-05	0.000814	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IL2—urinary bladder cancer	5.49e-05	0.000804	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	5.41e-05	0.000794	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CCND1—urinary bladder cancer	5.35e-05	0.000784	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MMP9—urinary bladder cancer	5.19e-05	0.000761	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CDKN1A—urinary bladder cancer	5.17e-05	0.000758	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CREBBP—urinary bladder cancer	5.17e-05	0.000758	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PTEN—urinary bladder cancer	5.16e-05	0.000756	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IGF1—urinary bladder cancer	5.11e-05	0.000749	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—EGFR—urinary bladder cancer	5.08e-05	0.000745	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	4.97e-05	0.000728	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—EP300—urinary bladder cancer	4.92e-05	0.000721	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—KRAS—urinary bladder cancer	4.8e-05	0.000704	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SRC—urinary bladder cancer	4.79e-05	0.000702	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.76e-05	0.000698	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TYMP—urinary bladder cancer	4.75e-05	0.000696	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	4.71e-05	0.000691	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NAT1—urinary bladder cancer	4.71e-05	0.000691	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—RHOA—urinary bladder cancer	4.68e-05	0.000686	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.56e-05	0.000668	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.34e-05	0.000636	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ERBB2—urinary bladder cancer	4.33e-05	0.000635	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TYMP—urinary bladder cancer	4.33e-05	0.000634	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.31e-05	0.000632	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NAT2—urinary bladder cancer	4.29e-05	0.000629	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MYC—urinary bladder cancer	4.29e-05	0.000629	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—EGFR—urinary bladder cancer	4.2e-05	0.000615	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.16e-05	0.000609	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CXCL8—urinary bladder cancer	4.11e-05	0.000602	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—HRAS—urinary bladder cancer	4.08e-05	0.000598	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—KRAS—urinary bladder cancer	3.96e-05	0.000581	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IL2—urinary bladder cancer	3.93e-05	0.000575	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NAT2—urinary bladder cancer	3.91e-05	0.000574	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.88e-05	0.000569	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CCND1—urinary bladder cancer	3.83e-05	0.000561	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MMP9—urinary bladder cancer	3.72e-05	0.000545	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—RRM2—urinary bladder cancer	3.71e-05	0.000543	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CDKN1A—urinary bladder cancer	3.7e-05	0.000543	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PTEN—urinary bladder cancer	3.69e-05	0.000541	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.66e-05	0.000537	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.57e-05	0.000523	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EP300—urinary bladder cancer	3.52e-05	0.000516	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—urinary bladder cancer	3.52e-05	0.000516	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ENO2—urinary bladder cancer	3.43e-05	0.000503	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	3.43e-05	0.000503	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SRC—urinary bladder cancer	3.43e-05	0.000502	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.41e-05	0.0005	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—RRM2—urinary bladder cancer	3.38e-05	0.000495	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—HRAS—urinary bladder cancer	3.37e-05	0.000494	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	3.33e-05	0.000488	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.28e-05	0.00048	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	3.13e-05	0.000459	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ENO2—urinary bladder cancer	3.13e-05	0.000459	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.11e-05	0.000456	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MYC—urinary bladder cancer	3.07e-05	0.00045	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	3.04e-05	0.000445	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EGFR—urinary bladder cancer	3e-05	0.00044	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.99e-05	0.000438	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.85e-05	0.000418	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—KRAS—urinary bladder cancer	2.84e-05	0.000416	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NQO1—urinary bladder cancer	2.77e-05	0.000405	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.68e-05	0.000393	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.58e-05	0.000378	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NQO1—urinary bladder cancer	2.52e-05	0.00037	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—urinary bladder cancer	2.52e-05	0.00037	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.45e-05	0.000359	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—HRAS—urinary bladder cancer	2.41e-05	0.000353	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.34e-05	0.000343	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	2.31e-05	0.000338	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.23e-05	0.000327	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.23e-05	0.000327	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—TYMS—urinary bladder cancer	2.15e-05	0.000314	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.13e-05	0.000313	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	2.12e-05	0.000311	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	2.12e-05	0.000311	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.1e-05	0.000308	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.06e-05	0.000302	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.06e-05	0.000302	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.04e-05	0.000298	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GPX1—urinary bladder cancer	2.03e-05	0.000298	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2e-05	0.000293	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.99e-05	0.000292	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.96e-05	0.000287	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.93e-05	0.000283	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.93e-05	0.000283	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.87e-05	0.000275	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.85e-05	0.000271	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.82e-05	0.000266	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.71e-05	0.00025	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.66e-05	0.000244	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.52e-05	0.000223	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.46e-05	0.000214	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.39e-05	0.000203	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.39e-05	0.000203	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.33e-05	0.000195	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.29e-05	0.000189	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.28e-05	0.000187	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.28e-05	0.000187	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.22e-05	0.000179	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.2e-05	0.000176	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.2e-05	0.000175	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.13e-05	0.000165	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.09e-05	0.00016	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.04e-05	0.000153	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—EP300—urinary bladder cancer	9.94e-06	0.000146	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTEN—urinary bladder cancer	9.51e-06	0.000139	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PPARG—urinary bladder cancer	9.14e-06	0.000134	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—EP300—urinary bladder cancer	9.07e-06	0.000133	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	8.78e-06	0.000129	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	7.19e-06	0.000105	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTEN—urinary bladder cancer	6.27e-06	9.19e-05	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—EP300—urinary bladder cancer	5.98e-06	8.76e-05	CbGpPWpGaD
